Saturday, December 19, 2015 12:11:12 PM
On December 14, 2015, Nemus Bioscience, Inc. (the “Company”) entered into two license agreements (the “License Agreements”) with the University of Mississippi, School of Pharmacy, or UM, pursuant to which UM granted the Company exclusive, perpetual licenses of all intellectual property related to UM8930, a pro-drug formulation of Cannabidiol, that UM has previously developed, including the right to sublicense, and we have identified target indications for development and commercialization by us. The two licenses are for delivery of UM8930 through ocular and rectal delivery. The Company entered into an option for the rights to use UM8930 for delivery by other means not yet agreed upon which is renewable every six months.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM